Gabapentin

Generic Name: Gabapentin

Brand Names: Gralise, Neurontin

Drug Type: Small Molecule

Chemical Formula: C_₉H_₁₇NO_₂

CAS Number: 60142-96-3

Unique Ingredient Identifier: 6CW7F3G59X

Background: Gabapentin is a structural analogue of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) that was first approved for use in the United States in 1993. It was originally developed as a novel anti-epileptic for the treatment of certain types of seizures - today it is also widely used to treat neuropathic pain. Gabapentin has some stark advantages ...

Indication: In the United States, gabapentin is officially indicated for the treatment of postherpetic neuralgia in adults and for the adjunctive treatment of partial-onset seizures, with or without secondary generalization, in patients 3 years of age and older. In Europe, gabapentin is indicated for adjunctive therapy in the treatment of partial-onset seizures, with or...

Associated Conditions: Partial-Onset Seizures, Peripheral Neuropathic Pain, Postherpetic Neuralgia

Associated Therapies: -

Clinical Trials

Gabapentin for Abstinence Initiation in Alcohol Dependence

Phase 2

Completed

Conditions: Alcohol Dependence

Interventions: Other: Placebo
Drug: Gabapentin

First Posted Date: 2010-06-10

Last Posted Date: 2019-04-24

Lead Sponsor: New York State Psychiatric Institute

Target Recruit Count: 40

Registration Number: NCT01141049

Locations: 🇺🇸
New York State Psychiatric Institute, New York, New York, United States
🇺🇸
Substance Treatment and Research Service (STARS), New York, New York, United States

Study To Assess The Effect Of Gabapentin, Diphenhydramine And Morphine On Cold Pain In Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: Gabapentin
Drug: Morphine
Drug: Diphenhydramine

First Posted Date: 2010-05-07

Last Posted Date: 2011-03-07

Lead Sponsor: Pfizer

Target Recruit Count: 19

Registration Number: NCT01119222

Locations: 🇧🇪
Pfizer Investigational Site, Bruxelles, Belgium

The Effect of Gabapentin on Thoracic Epidural Analgesia Following Thoracotomy

Phase 3

Completed

Conditions: Pain, Postoperative

Interventions: Drug: Placebo
Drug: Gabapentin

First Posted Date: 2010-05-05

Last Posted Date: 2014-08-05

Lead Sponsor: University of Aarhus

Target Recruit Count: 104

Registration Number: NCT01116583

Locations: 🇩🇰
Department of Cardiothoracic and Vascular Surgery, Aarhus University Hospital, Skejby, Aarhus N, Denmark

Oral Clonidine & Gabapentin: Improving Recovery and Pain Management After Outpatient With Major Orthopedic Surgery

Phase 4

Withdrawn

Conditions: Shoulder Arthroscopy
Knee Arthroscopy

Interventions: Drug: Gabapentin
Drug: Sugar pill
Drug: Clonidine

First Posted Date: 2010-04-29

Last Posted Date: 2015-09-14

Lead Sponsor: Cedars-Sinai Medical Center

Registration Number: NCT01112878

Locations: 🇺🇸
Cedars Sinai Medical Center, Los Angeles, California, United States

Fibromyalgia Treatment Trial With Gabapentin and Osteopathic Manipulative Medicine

Phase 3

Completed

Conditions: Fibromyalgia

Interventions: Procedure: Osteopathic Manipulative Medicine
Other: Gabapentin and Osteopathic Manipulative Medicine
Drug: Gabapentin

First Posted Date: 2010-04-21

Last Posted Date: 2013-08-28

Lead Sponsor: Good Samaritan Regional Medical Center, Oregon

Target Recruit Count: 41

Registration Number: NCT01107574

Locations: 🇺🇸
Touro University College of Osteoapathic Medicine, Vallejo, California, United States

Gabapentin for the Treatment of Pruritus Caused by Burn Injuries in Children

Phase 1

Withdrawn

Conditions: Pruritus

Interventions: Drug: Gabapentin

First Posted Date: 2010-03-25

Last Posted Date: 2013-08-20

Lead Sponsor: The Hospital for Sick Children

Registration Number: NCT01092520

Locations: 🇨🇦
The Hospital for Sick Children, Toronto, Ontario, Canada

Stanford Accelerated Recovery Trial (START)

Phase 3

Terminated

Conditions: Pain
Breast Cancer
Lung Cancer

Interventions: Drug: Lorazepam (active control)
Drug: Gabapentin
Drug: Placebo (inactive)

First Posted Date: 2010-02-11

Last Posted Date: 2022-05-05

Lead Sponsor: Stanford University

Target Recruit Count: 422

Registration Number: NCT01067144

Locations: 🇺🇸
Stanford University School of Medicine, Stanford, California, United States

Gabapentin in Functional Dyspepsia Refractory to Proton Pump Inhibition

Phase 3

Withdrawn

Conditions: Functional Dyspepsia

Interventions: Drug: Placebo
Drug: Gabapentin

First Posted Date: 2010-01-21

Last Posted Date: 2020-10-01

Lead Sponsor: 59th Medical Wing

Registration Number: NCT01052896

Locations: 🇺🇸
San Antonio Military Medical Center - North, San Antonio, Texas, United States
🇺🇸
San Antonio Military Medical Center - South, San Antonio, Texas, United States

Gabapentin in the Prevention of Nausea and Vomiting Induced by Chemotherapy

Phase 3

Completed

Conditions: Vomiting
Cisplatin Adverse Reaction

Interventions: Drug: Placebo
Drug: Gabapentin

First Posted Date: 2010-01-20

Last Posted Date: 2014-03-07

Lead Sponsor: Faculdade de Medicina do ABC

Target Recruit Count: 80

Registration Number: NCT01052844

Locations: 🇧🇷
Faculdade de Medicina do ABC, Santo André, São Paulo, Brazil

Plasma Gabapentin Concentration During and Following Cardiac Bypass

Phase 4

Completed

Conditions: Cardiopulmonary Bypass

Interventions: Drug: Gabapentin

First Posted Date: 2009-12-01

Last Posted Date: 2009-12-08

Lead Sponsor: Queen's University

Target Recruit Count: 16

Registration Number: NCT01022736

Locations: 🇨🇦
Kingston General Hospital, Kingston, Ontario, Canada

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy